NCT06900348

Brief Summary

It was planned in cross-sectional design in order to determine the specific prostate antigen level and some characteristics and the relationship evaluations and prostate specific antigen formation in individuals living in rural areas. It was planned to perform socio-demographic information formula, form including social information of health, prostate specific antigen test in the project data recording.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
308

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 22, 2025

Completed
3 days until next milestone

Study Start

First participant enrolled

March 25, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 28, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2025

Completed
Last Updated

March 30, 2025

Status Verified

March 1, 2025

Enrollment Period

4 months

First QC Date

March 22, 2025

Last Update Submit

March 28, 2025

Conditions

Prostate Carcinoma

Keywords

Prostate Carcinoma, Screening

Outcome Measures

Primary Outcomes (1)

  • PSA levels

    For ages 60-69: 0 - 4.5 ng/ml, For ages 70 and above: 0 - 6.5 ng/ml

    6 months

Interventions

PSA-Activated PSA-PAH1DIAGNOSTIC_TEST

Intravenous blood sample

Eligibility Criteria

Age55 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Male 55 years or older

You may qualify if:

  • Male
  • years or older

You may not qualify if:

  • Prostate treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant

Study Record Dates

First Submitted

March 22, 2025

First Posted

March 28, 2025

Study Start

March 25, 2025

Primary Completion

July 30, 2025

Study Completion

August 30, 2025

Last Updated

March 30, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share